{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:03:45Z","timestamp":1780484625027,"version":"3.54.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Spanish National Instituto de Salud Carlos III","award":["PI15\/00601"],"award-info":[{"award-number":["PI15\/00601"]}]},{"DOI":"10.13039\/501100006382","name":"Universidad de Oviedo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple sclerosis (MS) is a chronic neuroinflammatory disorder characterized by demyelination, oligodendrocyte (OLG) loss, and progressive neurological decline. While current disease-modifying therapies primarily target immune responses, they offer limited neuroprotective or remyelinating effects. Through its receptors, including cannabinoid receptor type 1 (CB\n                    <jats:sub>1<\/jats:sub>\n                    R) and the G protein-coupled receptor GPR55, the endocannabinoid system (ECS) has emerged as a promising therapeutic target due to its roles in neuronal survival and glial function. To better study the functional role of these receptors and their potential as targets for remyelinating therapies, we sought a human cell model that lacks endogenous expression of CB\n                    <jats:sub>1<\/jats:sub>\n                    R and GPR55. Quantitative PCR confirmed that human OLG-derived HOG cells do not express these receptors, providing a clean background for transfection-based functional studies. Using this system, we found that expressing either CB\n                    <jats:sub>1<\/jats:sub>\n                    R or GPR55 was sufficient to confer resistance to cuprizone (CPZ)-induced cytotoxicity, while co-expression produced a comparable level of protection but uncovered a distinct pharmacological interaction consistent with functional receptor crosstalk. In situ proximity ligation assays confirmed the formation of CB\n                    <jats:sub>1<\/jats:sub>\n                    R\/GPR55 receptor complexes in co-transfected cells. The protective effects were evident even under serum-containing conditions, suggesting that serum components may provide basal receptor activation. In serum-free conditions, selective activation of CB\n                    <jats:sub>1<\/jats:sub>\n                    R with arachidonyl-2'-chloroethylamide (ACEA) or GPR55 with CID1792197 enhanced cell survival, while the CB\n                    <jats:sub>1<\/jats:sub>\n                    R antagonist SR141716 blocked both ACEA- and CID1792197-induced protection. These cross-antagonistic interactions support the presence of heteromer-dependent signaling. Altogether, our findings identify CB\n                    <jats:sub>1<\/jats:sub>\n                    R\/GPR55 heteromers as novel modulators of OLG resilience and highlight their potential as therapeutic targets for promoting neuroprotection and remyelination in demyelinating diseases such as MS.\n                  <\/jats:p>","DOI":"10.1007\/s12035-026-05780-5","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:02:47Z","timestamp":1772560967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neuroprotective Role of Cannabinoid CB1 and GPR55 Receptors in a Cell Model of Multiple Sclerosis"],"prefix":"10.1007","volume":"63","author":[{"given":"Eva","family":"Mart\u00ednez-Pinilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Calatayud-Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Men\u00e9ndez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Villar-Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rivas-Santisteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Pel\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"5780_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378:169\u2013180. https:\/\/doi.org\/10.1056\/NEJMra1401483","journal-title":"N Engl J Med"},{"key":"5780_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrn3900","volume":"16","author":"M Calabrese","year":"2015","unstructured":"Calabrese M, Magliozzi R, Ciccarelli O et al (2015) Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 16:147\u2013158","journal-title":"Nat Rev Neurosci"},{"key":"5780_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11065-021-09479-3","volume":"31","author":"Y Cao","year":"2021","unstructured":"Cao Y, Diao W, Tian F et al (2021) Gray matter atrophy in the cortico-striatal-thalamic network and sensorimotor network in relapsing\u2013remitting and primary progressive multiple sclerosis. Neuropsychol Rev 31:703\u2013720","journal-title":"Neuropsychol Rev"},{"key":"5780_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","volume":"31","author":"J Oh","year":"2018","unstructured":"Oh J, Vidal-Jordana A, Montalban X (2018) Multiple sclerosis: clinical aspects. Curr Opin Neurol 31:752\u2013759","journal-title":"Curr Opin Neurol"},{"key":"5780_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-44615-3","volume":"9","author":"C Andica","year":"2019","unstructured":"Andica C, Hagiwara A, Kamagata K et al (2019) Gray matter alterations in early and late relapsing-remitting multiple sclerosis evaluated with synthetic quantitative magnetic resonance imaging. Sci Rep 9:1\u201310. https:\/\/doi.org\/10.1038\/s41598-019-44615-3","journal-title":"Sci Rep"},{"key":"5780_CR6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J 26:1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","journal-title":"Mult Scler J"},{"key":"5780_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2025.100553","volume":"38","author":"B Yamout","year":"2025","unstructured":"Yamout B (2025) Update in multiple sclerosis. eNeurolSci 38:100553. https:\/\/doi.org\/10.1016\/j.ensci.2025.100553","journal-title":"eNeurolSci"},{"key":"5780_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik K, Cortese M, Healy BC et al (2022) Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375:296\u2013301. https:\/\/doi.org\/10.1126\/science.abj8222","journal-title":"Science"},{"key":"5780_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3988\/JCN.2022.0208","volume":"19","author":"AB Baskaran","year":"2023","unstructured":"Baskaran AB, Grebenciucova E, Shoemaker T, Graham EL (2023) Current updates on the diagnosis and management of multiple sclerosis for the general neurologist. J Clin Neurol 19:217. https:\/\/doi.org\/10.3988\/JCN.2022.0208","journal-title":"J Clin Neurol"},{"key":"5780_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41582-022-00697-8","volume":"18","author":"J Correale","year":"2022","unstructured":"Correale J, Hohlfeld R, Baranzini SE (2022) The role of the gut microbiota in multiple sclerosis. Nat Rev Neurol 18:544\u2013558","journal-title":"Nat Rev Neurol"},{"key":"5780_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100039","author":"S Cavallo","year":"2020","unstructured":"Cavallo S (2020) Immune-mediated genesis of multiple sclerosis. J Transl Autoimmun. https:\/\/doi.org\/10.1016\/j.jtauto.2020.100039","journal-title":"J Transl Autoimmun"},{"key":"5780_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.599717","author":"HE Titus","year":"2020","unstructured":"Titus HE, Chen Y, Podojil JR et al (2020) Pre-clinical and clinical implications of \u201cinside-out\u201d vs. \u201coutside-in\u201d paradigms in multiple sclerosis etiopathogenesis. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2020.599717","journal-title":"Front Cell Neurosci"},{"key":"5780_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"5780_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/neuroglia6010006","volume":"6","author":"AV Arredondo-Robles","year":"2025","unstructured":"Arredondo-Robles AV, Rodr\u00edguez-L\u00f3pez KP, \u00c1vila-Avil\u00e9s RD (2025) Clinical management in multiple sclerosis. Neuroglia 6:6","journal-title":"Neuroglia"},{"key":"5780_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173","journal-title":"Lancet Neurol"},{"key":"5780_CR16","doi-asserted-by":"crossref","unstructured":"Goodin DS (2014) Glucocorticoid treatment of multiple sclerosis. In: Handbook of Clinical Neurology. pp 455\u2013464","DOI":"10.1016\/B978-0-444-52001-2.00020-0"},{"key":"5780_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s13311-022-01224-9","volume":"19","author":"N Krajnc","year":"2022","unstructured":"Krajnc N, Bsteh G, Berger T et al (2022) Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management. Neurotherapeutics 19:753\u2013773","journal-title":"Neurotherapeutics"},{"key":"5780_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122807","volume":"313","author":"SO Mohseni","year":"2025","unstructured":"Mohseni SO, Au KM, Issa W et al (2025) Multiple sclerosis treatments a review of current biomedical engineering approaches. Biomaterials 313:122807","journal-title":"Biomaterials"},{"key":"5780_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12647","volume":"502","author":"VA Deshmukh","year":"2013","unstructured":"Deshmukh VA, Tardif V, Lyssiotis CA et al (2013) A regenerative approach to the treatment of multiple sclerosis. Nature 502:327\u2013332. https:\/\/doi.org\/10.1038\/nature12647","journal-title":"Nature"},{"key":"5780_CR20","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Ruiz J, G\u00f3mez-Ruiz M, Garc\u00eda C, et al (2017) Modeling neurodegenerative disorders for developing cannabinoid-based neuroprotective therapies. In: Methods in enzymology. pp 175\u2013198","DOI":"10.1016\/bs.mie.2017.06.021"},{"key":"5780_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107456","volume":"209","author":"LIM Campagnoli","year":"2024","unstructured":"Campagnoli LIM, Marchesi N, Varesi A et al (2024) New therapeutic avenues in multiple sclerosis: is there a place for gut microbiota-based treatments? Pharmacol Res 209:107456","journal-title":"Pharmacol Res"},{"key":"5780_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000520560","volume":"21","author":"A Conte","year":"2022","unstructured":"Conte A, Silv\u00e1n CV (2022) Review of available data for the efficacy and effectiveness of Nabiximols oromucosal spray (Sativex\u00ae) in multiple sclerosis patients with moderate to severe spasticity. Neurodegener Dis 21:55\u201362","journal-title":"Neurodegener Dis"},{"key":"5780_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10072-022-06456-3","volume":"44","author":"M Pau","year":"2023","unstructured":"Pau M, Porta M, Spinicci G et al (2023) Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study. Neurol Sci 44:685\u2013691. https:\/\/doi.org\/10.1007\/s10072-022-06456-3","journal-title":"Neurol Sci"},{"key":"5780_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104745","author":"J Nicholas","year":"2023","unstructured":"Nicholas J, Lublin F, Klineova S et al (2023) Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/j.msard.2023.104745","journal-title":"Mult Scler Relat Disord"},{"key":"5780_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","volume":"16","author":"L Cristino","year":"2020","unstructured":"Cristino L, Bisogno T, Di Marzo V (2020) Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 16:9\u201329","journal-title":"Nat Rev Neurol"},{"key":"5780_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bcp.2018.08.016","volume":"157","author":"MS Aymerich","year":"2018","unstructured":"Aymerich MS, Aso E, Abellanas MA et al (2018) Cannabinoid pharmacology\/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem Pharmacol 157:67\u201384","journal-title":"Biochem Pharmacol"},{"key":"5780_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/glia.24280","volume":"71","author":"CE Martinez Ramirez","year":"2023","unstructured":"Martinez Ramirez CE, Ruiz-P\u00e9rez G, Stollenwerk TM et al (2023) Endocannabinoid signaling in the central nervous system. Glia 71:5\u201335. https:\/\/doi.org\/10.1002\/glia.24280","journal-title":"Glia"},{"key":"5780_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030833","author":"S Zou","year":"2018","unstructured":"Zou S, Kumar U (2018) Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19030833","journal-title":"Int J Mol Sci"},{"key":"5780_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00034","author":"M Mecha","year":"2020","unstructured":"Mecha M, Carrillo-Salinas FJ, Feli\u00fa A et al (2020) Perspectives on cannabis-based therapy of multiple sclerosis: a mini-review. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2020.00034","journal-title":"Front Cell Neurosci"},{"key":"5780_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041151","author":"RA Nouh","year":"2023","unstructured":"Nouh RA, Kamal A, Abdelnaser A (2023) Cannabinoids and multiple sclerosis: a critical analysis of therapeutic potentials and safety concerns. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15041151","journal-title":"Pharmaceutics"},{"key":"5780_CR31","doi-asserted-by":"crossref","unstructured":"Shu-Jung Hu S, Mackie K (2015) Distribution of the endocannabinoid system in the central nervous system. In: Handbook of Experimental Pharmacology. pp 59\u201393","DOI":"10.1007\/978-3-319-20825-1_3"},{"key":"5780_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","volume":"77","author":"M Glass","year":"1997","unstructured":"Glass M, Dragunow M, Faull RL, Dragunow M (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299\u2013318. https:\/\/doi.org\/10.1016\/S0306-4522(96)00428-9","journal-title":"Neuroscience"},{"key":"5780_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13724-x","author":"S Chou","year":"2022","unstructured":"Chou S, Ranganath T, Fish KN et al (2022) Cell type specific cannabinoid CB1 receptor distribution across the human and non-human primate cortex. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-022-13724-x","journal-title":"Sci Rep"},{"key":"5780_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/nyas.14413","volume":"1475","author":"E Mart\u00ednez-Pinilla","year":"2020","unstructured":"Mart\u00ednez-Pinilla E, Rico AJ, Rivas-Santisteban R et al (2020) Expression of cannabinoid CB1R\u2013GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum. Ann N Y Acad Sci 1475:34\u201342. https:\/\/doi.org\/10.1111\/nyas.14413","journal-title":"Ann N Y Acad Sci"},{"key":"5780_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/978-3-540-74805-2_14","volume":"184","author":"DM Lovinger","year":"2008","unstructured":"Lovinger DM (2008) Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 184:435\u2013477. https:\/\/doi.org\/10.1007\/978-3-540-74805-2_14","journal-title":"Handb Exp Pharmacol"},{"key":"5780_CR36","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/BPH.15538","volume":"178","author":"SP Alexander","year":"2021","unstructured":"Alexander SP, Christopoulos A, Davenport AP et al (2021) The concise guide to pharmacology 2021\/22: G protein-coupled receptors. Br J Pharmacol 178:S27\u2013S156. https:\/\/doi.org\/10.1111\/BPH.15538","journal-title":"Br J Pharmacol"},{"key":"5780_CR37","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2174\/092986710790980050","volume":"17","author":"R Pertwee","year":"2010","unstructured":"Pertwee R (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17:1360\u20131381. https:\/\/doi.org\/10.2174\/092986710790980050","journal-title":"Curr Med Chem"},{"key":"5780_CR38","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","volume":"176","author":"K Krishna Kumar","year":"2019","unstructured":"Krishna Kumar K, Shalev-Benami M, Robertson MJ et al (2019) Structure of a signaling cannabinoid receptor 1-G protein complex. Cell 176:448-458.e12. https:\/\/doi.org\/10.1016\/j.cell.2018.11.040","journal-title":"Cell"},{"key":"5780_CR39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","volume":"77","author":"M Glass","year":"1997","unstructured":"Glass M, Dragunow M, Faull RLM (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299\u2013318. https:\/\/doi.org\/10.1016\/S0306-4522(96)00428-9","journal-title":"Neuroscience"},{"key":"5780_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1601-183X.2009.00498.x","volume":"8","author":"QR Liu","year":"2009","unstructured":"Liu QR, Pan CH, Hishimoto A et al (2009) Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav 8:519\u2013530. https:\/\/doi.org\/10.1111\/j.1601-183X.2009.00498.x","journal-title":"Genes Brain Behav"},{"key":"5780_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881110367732","volume":"25","author":"JL Lanciego","year":"2011","unstructured":"Lanciego JL, Barroso-Chinea P, Rico AJ et al (2011) Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J Psychopharmacol 25:97\u2013104. https:\/\/doi.org\/10.1177\/0269881110367732","journal-title":"J Psychopharmacol"},{"key":"5780_CR42","doi-asserted-by":"crossref","unstructured":"Cabral GA, Ferreira GA, Jamerson MJ (2015) Endocannabinoids and the immune system in health and disease. In: Endocannabinoids. pp 185\u2013211","DOI":"10.1007\/978-3-319-20825-1_6"},{"key":"5780_CR43","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00429-020-02116-4","volume":"225","author":"E Mart\u00ednez-Pinilla","year":"2020","unstructured":"Mart\u00ednez-Pinilla E, Rico AJ, Rivas-Santisteban R et al (2020) Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates. Brain Struct Funct 225:2153\u20132164. https:\/\/doi.org\/10.1007\/s00429-020-02116-4","journal-title":"Brain Struct Funct"},{"key":"5780_CR44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2020.01.034","volume":"180","author":"DL Lynch","year":"2020","unstructured":"Lynch DL, Hurst DP, Reggio PH (2020) The nucleotide-free state of the cannabinoid CB2\/Gi complex. Cell 180:603\u2013604","journal-title":"Cell"},{"key":"5780_CR45","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13311-015-0381-7","volume":"12","author":"J Fern\u00e1ndez-Ruiz","year":"2015","unstructured":"Fern\u00e1ndez-Ruiz J, Moro MA, Mart\u00ednez-Orgado J (2015) Cannabinoids in neurodegenerative disorders and stroke\/brain trauma: from preclinical models to clinical applications. Neurotherapeutics 12:793\u2013806","journal-title":"Neurotherapeutics"},{"key":"5780_CR46","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.1021\/bi200010k","volume":"50","author":"E Kotsikorou","year":"2011","unstructured":"Kotsikorou E, Madrigal KE, Hurst DP et al (2011) Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 50:5633\u20135647. https:\/\/doi.org\/10.1021\/bi200010k","journal-title":"Biochemistry"},{"key":"5780_CR47","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1476-5381.2009.00625.x","volume":"160","author":"CM Henstridge","year":"2010","unstructured":"Henstridge CM, Balenga NA, Schr\u00f6der R et al (2010) GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160:604\u2013614. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00625.x","journal-title":"Br J Pharmacol"},{"key":"5780_CR48","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1124\/jpet.110.172650","volume":"337","author":"AJ Brown","year":"2011","unstructured":"Brown AJ, Daniels DA, Kassim M et al (2011) Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther 337:236\u2013246. https:\/\/doi.org\/10.1124\/jpet.110.172650","journal-title":"J Pharmacol Exp Ther"},{"key":"5780_CR49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1096\/fj.08-108670","volume":"23","author":"CM Henstridge","year":"2009","unstructured":"Henstridge CM, Balenga NAB, Ford LA et al (2009) The GPR55 ligand L\u2010\u03b1\u2010lysophosphatidylinositol promotes RhoA\u2010dependent Ca 2+ signaling and NFAT activation. FASEB J 23:183\u2013193. https:\/\/doi.org\/10.1096\/fj.08-108670","journal-title":"FASEB J"},{"key":"5780_CR50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/onc.2010.402","volume":"30","author":"C Andradas","year":"2011","unstructured":"Andradas C, Caffarel MM, P\u00e9rez-G\u00f3mez E et al (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30:245\u2013252. https:\/\/doi.org\/10.1038\/onc.2010.402","journal-title":"Oncogene"},{"key":"5780_CR51","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.bbrc.2017.05.145","volume":"489","author":"A Drzazga","year":"2017","unstructured":"Drzazga A, Sowinska A, Krzeminska A et al (2017) Lysophosphatidylcholine elicits intracellular calcium signaling in a GPR55-dependent manner. Biochem Biophys Res Commun 489:242\u2013247. https:\/\/doi.org\/10.1016\/j.bbrc.2017.05.145","journal-title":"Biochem Biophys Res Commun"},{"key":"5780_CR52","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.febslet.2009.05.028","volume":"583","author":"M Pietr","year":"2009","unstructured":"Pietr M, Kozela E, Levy R et al (2009) Differential changes in GPR55 during microglial cell activation. FEBS Lett 583:2071\u20132076. https:\/\/doi.org\/10.1016\/j.febslet.2009.05.028","journal-title":"FEBS Lett"},{"key":"5780_CR53","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1073\/pnas.1211204110","volume":"110","author":"S Sylantyev","year":"2013","unstructured":"Sylantyev S, Jensen TP, Ross RA, Rusakov DA (2013) Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A 110:5193\u20135198. https:\/\/doi.org\/10.1073\/pnas.1211204110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5780_CR54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pneurobio.2017.10.007","volume":"160","author":"V Chiurchi\u00f9","year":"2018","unstructured":"Chiurchi\u00f9 V, van der Stelt M, Centonze D, Maccarrone M (2018) The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog Neurobiol 160:82\u2013100","journal-title":"Prog Neurobiol"},{"key":"5780_CR55","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/cmdc.202000310","volume":"15","author":"S Maramai","year":"2020","unstructured":"Maramai S, Brindisi M (2020) Targeting endocannabinoid metabolism: an arrow with multiple tips against multiple sclerosis. ChemMedChem 15:1985\u20132003. https:\/\/doi.org\/10.1002\/cmdc.202000310","journal-title":"ChemMedChem"},{"key":"5780_CR56","doi-asserted-by":"publisher","first-page":"9742","DOI":"10.1523\/JNEUROSCI.22-22-09742.2002","volume":"22","author":"E Molina-Holgado","year":"2002","unstructured":"Molina-Holgado E, Vela JM, Ar\u00e9valo-Mart\u00edn A et al (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase\/Akt signaling. J Neurosci 22:9742\u201353","journal-title":"J Neurosci"},{"key":"5780_CR57","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/jnc.14098","volume":"142","author":"BS Basavarajappa","year":"2017","unstructured":"Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S (2017) Endocannabinoid system in neurodegenerative disorders. J Neurochem 142:624\u2013648. https:\/\/doi.org\/10.1111\/jnc.14098","journal-title":"J Neurochem"},{"key":"5780_CR58","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2174\/138161208785740117","volume":"14","author":"I Galve-Roperh","year":"2008","unstructured":"Galve-Roperh I, Aguado T, Palazuelos J, Guzman M (2008) Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 14:2279\u20132288. https:\/\/doi.org\/10.2174\/138161208785740117","journal-title":"Curr Pharm Des"},{"key":"5780_CR59","doi-asserted-by":"crossref","unstructured":"Ilyasov AA, Milligan CE, Pharr EP, Howlett AC (2018) The endocannabinoid system and oligodendrocytes in health and disease. Front Neurosci 12","DOI":"10.3389\/fnins.2018.00733"},{"key":"5780_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.neuropharm.2017.08.017","volume":"125","author":"M Celorrio","year":"2017","unstructured":"Celorrio M, Rojo-Bustamante E, Fern\u00e1ndez-Su\u00e1rez D et al (2017) GPR55: a therapeutic target for Parkinson\u2019s disease? Neuropharmacology 125:319\u2013332. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.017","journal-title":"Neuropharmacology"},{"key":"5780_CR61","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nchembio0309-131","volume":"5","author":"S Ferr\u00e9","year":"2009","unstructured":"Ferr\u00e9 S, Baler R, Bouvier M et al (2009) Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5:131\u2013134","journal-title":"Nat Chem Biol"},{"key":"5780_CR62","doi-asserted-by":"publisher","unstructured":"Franco R, Mart\u00ednez-Pinilla E, Lanciego JL, Navarro G (2016) Basic pharmacological and structural evidence for class A G-protein-coupled receptor heteromerization. Front Pharmacol 7:. https:\/\/doi.org\/10.3389\/fphar.2016.00076","DOI":"10.3389\/fphar.2016.00076"},{"key":"5780_CR63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1515\/bmc-2018-0013","volume":"9","author":"R Franco","year":"2018","unstructured":"Franco R, Aguinaga D, Jim\u00e9nez J et al (2018) Biased receptor functionality versus biased agonism in G-protein-coupled receptors. Biomol Concepts 9:143\u2013154","journal-title":"Biomol Concepts"},{"key":"5780_CR64","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1007\/S12035-019-1495-4","volume":"56","author":"E Mart\u00ednez-Pinilla","year":"2019","unstructured":"Mart\u00ednez-Pinilla E, Aguinaga D, Navarro G et al (2019) Targeting CB 1 and GPR55 endocannabinoid receptors as a potential neuroprotective approach for Parkinson\u2019s disease. Mol Neurobiol 56:5900\u20135910. https:\/\/doi.org\/10.1007\/S12035-019-1495-4","journal-title":"Mol Neurobiol"},{"key":"5780_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2014.06.017","author":"E Mart\u00ednez-Pinilla","year":"2014","unstructured":"Mart\u00ednez-Pinilla E, Reyes-Resina I, O\u00f1atibia-Astibia A et al (2014) CB<inf>1<\/inf>and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. Exp Neurol. https:\/\/doi.org\/10.1016\/j.expneurol.2014.06.017","journal-title":"Exp Neurol"},{"key":"5780_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084176","author":"C Men\u00e9ndez-P\u00e9rez","year":"2024","unstructured":"Men\u00e9ndez-P\u00e9rez C, Rivas-Santisteban R, Del Valle E et al (2024) Heteromers formed by GPR55 and either cannabinoid CB1 or CB2 receptors are upregulated in the prefrontal cortex of multiple sclerosis patients. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25084176","journal-title":"Int J Mol Sci"},{"key":"5780_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1750-3639.2001.tb00385.x","volume":"11","author":"GK Matsushima","year":"2006","unstructured":"Matsushima GK, Morell P (2006) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107\u2013116. https:\/\/doi.org\/10.1111\/j.1750-3639.2001.tb00385.x","journal-title":"Brain Pathol"},{"key":"5780_CR68","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2174\/187152712801661284","volume":"11","author":"B van der Star","year":"2012","unstructured":"van der Star B, Vogel D, Kipp M et al (2012) In vitro and in vivo models of multiple sclerosis. CNS Neurol Disord - Drug Targets 11:570\u2013588. https:\/\/doi.org\/10.2174\/187152712801661284","journal-title":"CNS Neurol Disord - Drug Targets"},{"key":"5780_CR69","doi-asserted-by":"publisher","DOI":"10.1177\/1759091414551955","author":"S Hh","year":"2014","unstructured":"Hh S, Kk B, Dc P et al (2014) A new model of cuprizone-mediated demyelination\/remyelination. ASN Neuro. https:\/\/doi.org\/10.1177\/1759091414551955","journal-title":"ASN Neuro"},{"key":"5780_CR70","doi-asserted-by":"crossref","unstructured":"Zirngibl M, Assinck P, Sizov A, et al (2022) Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination. Mol Neurodegener 17","DOI":"10.1186\/s13024-022-00538-8"},{"key":"5780_CR71","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/nan.12405","volume":"44","author":"D Carassiti","year":"2018","unstructured":"Carassiti D, Altmann DR, Petrova N et al (2018) Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex. Neuropathol Appl Neurobiol 44:377\u2013390. https:\/\/doi.org\/10.1111\/nan.12405","journal-title":"Neuropathol Appl Neurobiol"},{"key":"5780_CR72","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/ar.24216","volume":"302","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Cai L, Fan K et al (2019) The spatial and temporal characters of demyelination and remyelination in the cuprizone animal model. Anat Rec 302:2020\u20132029. https:\/\/doi.org\/10.1002\/ar.24216","journal-title":"Anat Rec"},{"key":"5780_CR73","first-page":"1585","volume":"26","author":"T Skripuletz","year":"2011","unstructured":"Skripuletz T, Gudi V, Hackstette D, Stangel M (2011) De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol Histopathol 26:1585\u20131597","journal-title":"Histol Histopathol"},{"key":"5780_CR74","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.bbi.2020.01.021","volume":"87","author":"MK Sen","year":"2020","unstructured":"Sen MK, Almuslehi MSM, Coorssen JR et al (2020) Behavioural and histological changes in cuprizone-fed mice. Brain Behav Immun 87:508\u2013523. https:\/\/doi.org\/10.1016\/j.bbi.2020.01.021","journal-title":"Brain Behav Immun"},{"key":"5780_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci11020272","volume":"11","author":"E Mart\u00ednez\u2010Pinilla","year":"2021","unstructured":"Mart\u00ednez\u2010Pinilla E, Rubio\u2010sard\u00f3n N, Villar\u2010conde S et al (2021) Cuprizone\u2010induced neurotoxicity in human neural cell lines is mediated by a reversible mitochondrial dysfunction: relevance for demyelination models. Brain Sci 11:1\u201316. https:\/\/doi.org\/10.3390\/brainsci11020272","journal-title":"Brain Sci"},{"key":"5780_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031260","volume":"22","author":"E Mart\u00ednez-Pinilla","year":"2021","unstructured":"Mart\u00ednez-Pinilla E, Rubio-Sard\u00f3n N, Pel\u00e1ez R et al (2021) Neuroprotective effect of Apolipoprotein D in cuprizone-induced cell line models: a potential therapeutic approach for multiple sclerosis and demyelinating diseases. Int J Mol Sci 22:1260. https:\/\/doi.org\/10.3390\/ijms22031260","journal-title":"Int J Mol Sci"},{"key":"5780_CR77","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF03159976","volume":"16","author":"GR Post","year":"1992","unstructured":"Post GR, Dawson G (1992) Characterization of a cell line derived from a human oligodendroglioma. Mol Chem Neuropathol 16:303\u2013317. https:\/\/doi.org\/10.1007\/BF03159976","journal-title":"Mol Chem Neuropathol"},{"key":"5780_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089141","author":"R Bello-Morales","year":"2014","unstructured":"Bello-Morales R, Crespillo AJ, Garc\u00eda B et al (2014) The effect of cellular differentiation on HSV-1 infection of oligodendrocytic cells. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0089141","journal-title":"PLoS One"},{"key":"5780_CR79","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1038\/emboj.2011.139","volume":"30","author":"R Rozenfeld","year":"2011","unstructured":"Rozenfeld R, Gupta A, Gagnidze K et al (2011) AT1R-CB1 R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J 30:2350\u20132363. https:\/\/doi.org\/10.1038\/emboj.2011.139","journal-title":"EMBO J"},{"key":"5780_CR80","doi-asserted-by":"publisher","first-page":"21960","DOI":"10.1074\/jbc.M114.561761","volume":"289","author":"E Moreno","year":"2014","unstructured":"Moreno E, Andradas C, Medrano M et al (2014) Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J Biol Chem 289:21960\u201321972. https:\/\/doi.org\/10.1074\/jbc.M114.561761","journal-title":"J Biol Chem"},{"key":"5780_CR81","first-page":"1","volume":"9","author":"M Zhang","year":"2024","unstructured":"Zhang M, Chen T, Lu X et al (2024) G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery. Signal Transduct Target Ther 9:1\u201343","journal-title":"Signal Transduct Target Ther"},{"key":"5780_CR82","doi-asserted-by":"publisher","first-page":"44234","DOI":"10.1074\/jbc.M112.364109","volume":"287","author":"J Kargl","year":"2012","unstructured":"Kargl J, Balenga N, Parzmair GP et al (2012) The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem 287:44234\u201344248. https:\/\/doi.org\/10.1074\/jbc.M112.364109","journal-title":"J Biol Chem"},{"key":"5780_CR83","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.tips.2008.12.004","volume":"30","author":"RA Ross","year":"2009","unstructured":"Ross RA (2009) The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30:156\u2013163","journal-title":"Trends Pharmacol Sci"},{"key":"5780_CR84","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.pharmthera.2010.02.004","volume":"126","author":"H Sharir","year":"2010","unstructured":"Sharir H, Abood ME (2010) Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126:301\u2013313","journal-title":"Pharmacol Ther"},{"key":"5780_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pbr.2025.07.006","volume":"296","author":"CM Queiroz","year":"2025","unstructured":"Queiroz CM, de Oliveira KL, da Silva CRP et al (2025) Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. Prog Brain Res 296:1\u201328. https:\/\/doi.org\/10.1016\/bs.pbr.2025.07.006","journal-title":"Prog Brain Res"},{"key":"5780_CR86","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1100\/tsw.2007.197","volume":"7","author":"R Franco","year":"2007","unstructured":"Franco R, Casad\u00f3 V, Cort\u00e9s A et al (2007) Basic concepts in G-protein-coupled receptor homo- and heterodimerization. The Scientific World JOURNAL 7:48\u201357","journal-title":"The Scientific World JOURNAL"},{"key":"5780_CR87","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s12264-013-1317-z","volume":"29","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Guo TB, Lu H (2013) Promoting remyelination for the treatment of multiple sclerosis: opportunities and challenges. Neurosci Bull 29:144\u2013154","journal-title":"Neurosci Bull"},{"key":"5780_CR88","doi-asserted-by":"publisher","first-page":"136","DOI":"10.56367\/oag-037-10382","volume":"37","author":"TM DeSilva","year":"2023","unstructured":"DeSilva TM (2023) Remyelinating versus neuroprotective therapies for multiple sclerosis. Open Access Gov 37:136\u2013137. https:\/\/doi.org\/10.56367\/oag-037-10382","journal-title":"Open Access Gov"},{"key":"5780_CR89","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1750-3639.2011.00477.x","volume":"21","author":"H Zhang","year":"2011","unstructured":"Zhang H, Hilton DA, Hanemann CO, Zajicek J (2011) Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D-evidence for altered expression in multiple sclerosis. Brain Pathol 21:544\u2013557. https:\/\/doi.org\/10.1111\/j.1750-3639.2011.00477.x","journal-title":"Brain Pathol"},{"key":"5780_CR90","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1523\/JNEUROSCI.4814-06.2007","volume":"27","author":"C Benito","year":"2007","unstructured":"Benito C, Romero JP, Tol\u00f3n RM et al (2007) Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27:2396\u20132402. https:\/\/doi.org\/10.1523\/JNEUROSCI.4814-06.2007","journal-title":"J Neurosci"},{"key":"5780_CR91","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12035-020-02148-1","volume":"58","author":"R Moreno-Luna","year":"2021","unstructured":"Moreno-Luna R, Esteban PF, Paniagua-Torija B et al (2021) Heterogeneity of the endocannabinoid system between cerebral cortex and spinal cord oligodendrocytes. Mol Neurobiol 58:689\u2013702","journal-title":"Mol Neurobiol"},{"key":"5780_CR92","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/1570159x15666170717120343","volume":"17","author":"JM Vega-Riquer","year":"2019","unstructured":"Vega-Riquer JM, Mendez-Victoriano G, Morales-Luckie RA, Gonzalez-Perez O (2019) Five decades of cuprizone, an updated model to replicate demyelinating diseases. Curr Neuropharmacol 17:129\u2013141. https:\/\/doi.org\/10.2174\/1570159x15666170717120343","journal-title":"Curr Neuropharmacol"},{"key":"5780_CR93","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1021\/acsptsci.0c00214","volume":"4","author":"I Reynoso-Moreno","year":"2021","unstructured":"Reynoso-Moreno I, Tietz S, Vallini E et al (2021) Selective endocannabinoid reuptake inhibitor WOBE437 reduces disease progression in a mouse model of multiple sclerosis. ACS Pharmacology & Translational Science 4:765\u2013779. https:\/\/doi.org\/10.1021\/acsptsci.0c00214","journal-title":"ACS Pharmacology & Translational Science"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-05780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-05780-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-05780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:02:49Z","timestamp":1772560969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-05780-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5780"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-05780-5","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"482"}}